此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

患有创伤后应激障碍的退伍军人使用大麻 (FOCUS) 的功能性结果 (FOCUS)

2026年11月12日 更新者:VA Office of Research and Development

Posttraumatic stress disorder (PTSD) is a disabling psychiatric disorder that affects 20%-30% of U.S. Veterans. PTSD is strongly associated with increased risk for substance abuse comorbidity, including cannabis use disorder. Multiple states now include PTSD as a condition for which patients can be legally prescribed medical marijuana, despite the fact that there has not been a single large-scale randomized clinical trial demonstrating the efficacy of cannabis to treat PTSD to date. The overall objective of the current proposal is to study the impact of reduced cannabis use on functioning among Veterans with PTSD. The investigators will evaluate the relationship between cannabis use and daily functioning among cannabis users and heavy cannabis users. The central hypothesis is that reductions in cannabis use will lead to positive changes in the functional outcomes of Veterans. The rationale for this research is that it will provide the first and only real-time data concerning the impact of reduced cannabis use on daily functioning among Veterans with PTSD.

研究概览

地位

完全的

条件

干预/治疗

详细说明

Posttraumatic stress disorder (PTSD) is a disabling psychiatric disorder that affects 20%-30% of U.S. Veterans. PTSD is strongly associated with increased risk for substance abuse comorbidity, including cannabis use disorder; however, multiple states now include PTSD as a condition for which patients can be legally prescribed medical marijuana, despite the fact that there has not been a single large-scale randomized clinical trial demonstrating the efficacy of cannabis to treat PTSD to date. The overall objective of the current proposal is to prospectively study the impact of reduced cannabis use on psychosocial functioning among Veterans with PTSD. To do so, the investigators will first use ecological momentary assessment (EMA) methods to evaluate the relationship between cannabis use and daily functioning among Veterans with PTSD. Next, the investigators will use mobile contingency management (CM) and EMA to assess the impact of reduced cannabis use on daily functioning among Veterans with PTSD who are heavy cannabis users. The central hypothesis is that reductions in cannabis use will lead to positive changes in the functional outcomes of Veterans. The rationale for this research is that it will provide the first and only real-time data concerning the impact of reduced cannabis use on daily functioning among Veterans with PTSD. As a result, this innovative and timely project has the potential to significantly advance VHA healthcare and will directly inform the ongoing national debate concerning the impact of cannabis use on the long-term functional recovery of Veterans with PTSD.

研究类型

介入性

注册 (实际的)

65

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • North Carolina
      • Durham、North Carolina、美国、27705-3875
        • Durham VA Medical Center, Durham, NC

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Veteran status
  • Ability to speak and write fluent English
  • Current PTSD diagnosis
  • Use of cannabis on 13+ days in the past month (i.e., use on 3+ days per week)

Exclusion Criteria:

Participants will be excluded if they:

  • Have experienced a change in their psychiatric medication regimen during the past month (e.g., a new medication has been prescribed or the dose of an existing medication has been changed), or expect to experience a such a change during the course of the study
  • Are receiving non-study CUD treatment
  • Meet diagnostic criteria for bipolar disorder or schizophrenia (note that the SCID-5 (First et al., 2015) will be used to diagnoses these and other disorders)
  • Become imprisoned
  • Become hospitalized for psychiatric reasons
  • Report imminent risk for suicide or homicide
  • Meet current criteria for a substance use disorder other than cannabis use disorder or tobacco

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Contingency Management (CM)

Mobile contingency management (CM) will be used to promote reductions in cannabis use among Veterans with PTSD who are heavy cannabis users. CM is an intensive behavioral therapy in which participants are paid to reduce substance use.

Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.

其他名称:
  • 移动应急管理 (mCM)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in functional impairment as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS)
大体时间:Baseline and post-treatment (approximately six weeks)

Functional impairment will be measured by the simple score on the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS). This measure has a scoring range of 0 to 144, with lower scores indicating lower functional impairment.

Baseline and post-treatment (approximately six weeks)
Change in functional impairment as measured by the Inventory of Psychosocial Functioning (IPF)
大体时间:Baseline and post-treatment (approximately six weeks)

Functional impairment will be measured by the Inventory of Psychosocial Functioning (IPF). This measure has a scoring range of 0 to 480, with lower scores indicating higher functional impairment.

Baseline and post-treatment (approximately six weeks)
Change in psychiatric distress
大体时间:Baseline and post-treatment (approximately six weeks)

Psychiatric distress will be measured by the 90-item Symptom Checklist (SCL-90). This measure has a scoring range of 0 to 360, with lower scores indicating lower distress related to mental health.

Baseline and post-treatment (approximately six weeks)
Change in quality of life, as measured by the WHOQOL-BREF
大体时间:Baseline and post-treatment (approximately six weeks)

Quality of life will be measured with the World Health Organization Quality of Life Brief (WHOQOL-BREF). The measure has a scoring range of 0 to 100, with higher scores denoting a higher quality of life.

Baseline and post-treatment (approximately six weeks)
Change in quality of life, as measured by the Quality of Life Scale
大体时间:Baseline and post-treatment (approximately six weeks)

Quality of life will be measured with the 16-item Quality of Life Scale. The measure has a scoring range of 6 to 112, with higher scores denoting a higher quality of life.

Baseline and post-treatment (approximately six weeks)
Change in number of days of drugged driving as measured by timeline follow-back
大体时间:Baseline and post-treatment (approximately six weeks)

Number of days of drugged driving in the past month will be self-reported by participants using a Timeline Follow-Back Interview.

Baseline and post-treatment (approximately six weeks)
Change in cannabis use
大体时间:Baseline and post-treatment (approximately six weeks)

Cannabis use, as measured in milligrams, will be measured by taking the product of number of days used and amount used per day in the previous week.

Baseline and post-treatment (approximately six weeks)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Jean C Beckham, PhD、Durham VA Medical Center, Durham, NC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年1月26日

初级完成 (实际的)

2026年6月12日

研究完成 (实际的)

2026年6月12日

研究注册日期

首次提交

2020年9月18日

首先提交符合 QC 标准的

2020年9月24日

首次发布 (实际的)

2020年9月25日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • D3276-R
  • 1I01RX003276-01A2 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

The investigators do not plan to attend individual participant data.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.